TC
AKRO

TwinBeech Capital’s Akero Therapeutics AKRO Stock Holding History

TwinBeech Capital’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,022
Closed -$1.39M – 553
2025
Q2 		$1.39M Buy
+26,022
New +$1.18M 0.03% 372
2024
Q2 		– Sell
-98,982
Closed -$2.5M – 507
2024
Q1 		$2.5M Buy
+98,982
New +$2.38M 0.05% 311
2023
Q4 		– Sell
-54,780
Closed -$2.77M – 622
2023
Q3 		$2.77M Buy
+54,780
New +$2.55M 0.05% 360
2023
Q2 		– Sell
-20,595
Closed -$788K – 571
2023
Q1 		$788K Buy
+20,595
New +$918K 0.02% 474

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TwinBeech Capital's AKRO Position: Q3 2025 in Review

TwinBeech Capital sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 26,022 shares — an estimated $1.39M sold.

TwinBeech Capital first reported a position in AKRO in Q1 2023 and held it in 4 quarters. The position peaked at $2.77M in Q3 2023. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • TwinBeech Capital reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • TwinBeech Capital sold 26,022 Akero Therapeutics shares in Q3 2025, an estimated $1.39M.
  • TwinBeech Capital first reported a position in Akero Therapeutics in Q1 2023 and held it in 4 quarters.
  • TwinBeech Capital's Akero Therapeutics position peaked at $2.77M in Q3 2023.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on TwinBeech Capital's 13F filing for Q3 2025, filed 14 Nov 2025.